Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Am Acad Dermatol. 2020 Jan 31;83(3):955–957. doi: 10.1016/j.jaad.2020.01.059

Table 1.

FAERS data through Q1 2018: Reports for bullous disorders by drug name

Drug (Class) N Safety Signal 5 for BD Date of FDA Approval
Nivolumab (PD-1) 99 Yes Dec 22, 2014
Pembrolizumab (PD-1) 43 Yes Sep 2, 2014
Atezolizumab (PD-L1) 7 Yes May 18, 2016
Durvalumab (PD-L1) 4 Yes May 1, 2017
Avelumab (PD-L1) 0 No Mar 23, 2017